MX366936B - Uso de un anticuerpo específico alfa4beta7. - Google Patents
Uso de un anticuerpo específico alfa4beta7.Info
- Publication number
- MX366936B MX366936B MX2014006265A MX2014006265A MX366936B MX 366936 B MX366936 B MX 366936B MX 2014006265 A MX2014006265 A MX 2014006265A MX 2014006265 A MX2014006265 A MX 2014006265A MX 366936 B MX366936 B MX 366936B
- Authority
- MX
- Mexico
- Prior art keywords
- specific antibody
- dimer
- hetero
- administration
- condition
- Prior art date
Links
- 239000000833 heterodimer Substances 0.000 title abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000032258 transport Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563430P | 2011-11-23 | 2011-11-23 | |
| US201261599221P | 2012-02-15 | 2012-02-15 | |
| PCT/US2012/066345 WO2013078375A2 (en) | 2011-11-23 | 2012-11-21 | Administration of alpha4beta7 hetero-dimer-specific antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014006265A MX2014006265A (es) | 2014-10-24 |
| MX366936B true MX366936B (es) | 2019-07-31 |
Family
ID=47291275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014006265A MX366936B (es) | 2011-11-23 | 2012-11-21 | Uso de un anticuerpo específico alfa4beta7. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9914779B2 (enExample) |
| EP (2) | EP2782599B1 (enExample) |
| JP (2) | JP6203740B2 (enExample) |
| AU (1) | AU2012340621B2 (enExample) |
| CA (1) | CA2856866C (enExample) |
| MX (1) | MX366936B (enExample) |
| WO (1) | WO2013078375A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2890600T3 (es) | 2014-05-16 | 2022-01-20 | Protagonist Therapeutics Inc | Péptidos de tioéter antagonistas de integrina alfa4beta7 |
| CA3154741A1 (en) * | 2019-09-20 | 2021-03-25 | University Of Florida Research Foundation, Incorporated | Detection of antibodies against ran proteins from serum and tissue lysates |
| BR112022013628A2 (pt) * | 2020-01-10 | 2022-11-22 | Protagonist Therapeutics Inc | Métodos para tratar doenças inflamatórias intestinais com antagonistas de integrina alpha-4 beta-7 |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN116482345B (zh) * | 2023-06-16 | 2023-09-22 | 军科正源（北京）药物研究有限责任公司 | 用于检测双靶点药物受体占有率的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| MY162179A (en) * | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| JP2010521966A (ja) | 2007-03-20 | 2010-07-01 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | α４β７インテグリンに結合するヒト化免疫グロブリンをコードする核酸 |
| KR101361905B1 (ko) * | 2008-05-16 | 2014-02-21 | 제넨테크, 인크. | 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도 |
| KR101346530B1 (ko) | 2009-03-20 | 2013-12-31 | 암젠 인크 | 알파-4-베타-7 이종이량체 특이적 길항제 항체 |
| EA201891433A3 (ru) | 2010-01-15 | 2019-02-28 | Кирин-Эмджен, Инк. | Состав антитела и терапевтические режимы |
-
2012
- 2012-11-21 WO PCT/US2012/066345 patent/WO2013078375A2/en not_active Ceased
- 2012-11-21 EP EP12795715.7A patent/EP2782599B1/en active Active
- 2012-11-21 CA CA2856866A patent/CA2856866C/en active Active
- 2012-11-21 EP EP18196666.4A patent/EP3492099A1/en not_active Withdrawn
- 2012-11-21 JP JP2014543572A patent/JP6203740B2/ja active Active
- 2012-11-21 US US14/360,087 patent/US9914779B2/en active Active
- 2012-11-21 MX MX2014006265A patent/MX366936B/es active IP Right Grant
- 2012-11-21 AU AU2012340621A patent/AU2012340621B2/en active Active
-
2017
- 2017-08-30 JP JP2017165395A patent/JP6564435B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140322209A1 (en) | 2014-10-30 |
| WO2013078375A2 (en) | 2013-05-30 |
| JP6564435B2 (ja) | 2019-08-21 |
| US9914779B2 (en) | 2018-03-13 |
| EP2782599B1 (en) | 2019-10-16 |
| WO2013078375A3 (en) | 2013-10-03 |
| EP2782599A2 (en) | 2014-10-01 |
| CA2856866A1 (en) | 2013-05-30 |
| JP2018031780A (ja) | 2018-03-01 |
| EP3492099A1 (en) | 2019-06-05 |
| CA2856866C (en) | 2022-07-12 |
| JP2015505822A (ja) | 2015-02-26 |
| AU2012340621A1 (en) | 2014-05-29 |
| JP6203740B2 (ja) | 2017-09-27 |
| AU2012340621B2 (en) | 2017-10-12 |
| MX2014006265A (es) | 2014-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201305508B (en) | Use of the phytocannabinoid (cbd)in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy | |
| IL231282A0 (en) | Antibodies to 9pcsk and their uses | |
| GB2557508B (en) | A device comprising non-native pancreatic ß cells and use in treating diseases such as diabetes | |
| EP2776115A4 (en) | MEDICAL PLASTER AND INJECTOR SYSTEM | |
| WO2013005053A3 (en) | Progenitor cells of mesodermal lineage | |
| NZ719368A (en) | Combination therapy of antibodies against human csf-1r and uses thereof | |
| EP2616123A4 (en) | NEEDLE-FREE INJECTORS AND DESIGN PARAMETERS FOR OPTIMIZED INJECTION PERFORMANCE | |
| EP2810890A4 (en) | BAG AND BAG WITH INCLUDED CONTENTS | |
| PL2888284T3 (pl) | Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie | |
| IL227312A0 (en) | Lidocaine administration regimen for long-term treatment of bladder pain and voiding irritation | |
| EP2612817A4 (en) | FUNNELED AND EQUIPPED METHOD OF DISPOSAL FOR MEDICINAL PRODUCTS | |
| ZA201309683B (en) | Neutraling prolactin receptor antibody mat3 and its therapeutic use | |
| SG10201505644PA (en) | Artificial intelligence and methods for relating herbal ingredients with illnesses in traditional chinese medicine | |
| GB201012859D0 (en) | Computing device with improved function selection and method | |
| MX366936B (es) | Uso de un anticuerpo específico alfa4beta7. | |
| WO2014153385A3 (en) | Methods of treating metabolic disorders | |
| WO2013083826A3 (en) | Glp-1 agonists | |
| NZ628454A (en) | Combination therapy of anti-mif antibodies and glucocorticoids | |
| GB2509663A (en) | Treatment of adrenal insufficiency | |
| MX2015012074A (es) | Composicion farmaceutica de mesalamina con multiples elementos de dosis para viabilidad de administracion reducida. | |
| HUE068523T2 (hu) | Módszerek élelemfelvétel és élelemvisszatartás elõsegítésére | |
| MX351765B (es) | Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares. | |
| EP2566877A4 (en) | METHOD FOR REDUCING SYMPTOMS IN PATIENTS WITH INDIVIDUAL DOSAGE FORMS WITH STEP BY STEP RELEASE | |
| GB2495572B (en) | Golf bags with retention system and methods to manufacture golf bags | |
| EP2921130A4 (en) | DENTAL IMPLANT HAVING A FIRST AND A SECOND INTERNAL THREAD |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |